AL-0433 / Eilean Therapeutics - LARVOL DELTA

Discovery of a novel, selective brain penetrant CDK4 inhibitor for targeted cancer therapy (AACR 2026) - "Approved CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are associated with hematologic toxicity, including neutropenia, linked to CDK6 rather than CDK4 inhibition. AL-0433 is a promising, AI-designed, selective CDK4 inhibitor with broad activity across breast, ovarian, and glioblastoma cell lines. Its favorable PK profile, preclinical efficacy, and rational design strategy support further clinical development"

Brain Cancer • Breast Cancer • Glioblastoma • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • CCND1 • CCND3 • CDK1 • CDK2 • CDK9 • CDKN2A